Tech Company Financing Transactions
Neukio Biotherapeutics Funding Round
Neukio Biotherapeutics, based in Shanghai, raised $50 million in investment from CD Capital, Alwin Capital and IDG Capital Partners.
Transaction Overview
Company Name
Announced On
9/2/2022
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Proceeds Purpose
The funds raised will play important roles in accelerating the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and supporting team recruitment and expansion.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3F, Building 7-5, No. 215 South Fute Road
Shanghai, Undisclosed
CN
Shanghai, Undisclosed
CN
Phone
Undisclosed
Website
Email Address
Overview
Established in June 2021 at the Life Science Park of the Shanghai Free Trade Zone, Neukio focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products. The management team has rich cell therapy experience, CEO and other key managers have led the Fosun Kite JV from the start and successfully launched the first CAR-T product Yescarta® commercialization in China (tech transfer, manufacturing, clinical trials and regulatory approval) in less than three years. Supported by renowned VC investors including Lilly Asia Ventures, IDG Capital and Sherpa Capital, with a $40M angel round funding in August 2021.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Wang
VP - R & D
Lei Zhang
Browse more venture capital transactions:
Prev: 9/2/2022: Cantos Venture venture capital transaction
Next: 9/2/2022: Funxtion venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs